Zenas BioPharma (ZBIO) Other financing activities (2023 - 2026)
Zenas BioPharma (ZBIO) posted quarterly Other financing activities of $367000.0 for Q1 2026, up 270.71% year-over-year from $99000.0 in Q1 2025, and up 123.75% quarter-over-quarter from -$1.5 million in Q3 2025.
Zenas BioPharma (ZBIO) Other financing activities (2023 - 2026) Analysis & Trends
Zenas BioPharma's Other financing activities history runs 4 years deep, the most recent figure standing at $367000.0 for Q1 2026.
- In Q1 2026, Other financing activities rose 270.71% year-over-year to $367000.0; the TTM figure through Mar 2026 stood at $544000.0 (down 99.79% YoY), while the FY2025 annual figure was $276000.0, changed 0.36% from the prior year.
- Other financing activities for Q1 2026 stood at $367000.0, up from -$1.5 million in the prior quarter.
- The five-year high for Other financing activities was $258.7 million in Q3 2024, with the low at -$1.5 million in Q3 2025.
- The 4-year median for Other financing activities is $99000.0 (2025), against an average of $28.8 million.
- Peak annual rise in Other financing activities reached 1288.71% in 2025, while the deepest fall reached 100.6% in 2025.
- Zenas BioPharma's Other financing activities stood at $50000.0 in 2023, then soared by 54.0% to $77000.0 in 2024, then sank by 2106.49% to -$1.5 million in 2025, then jumped by 123.75% to $367000.0 in 2026.
- Business Quant data shows ZBIO's Other financing activities at $367000.0 in Q1 2026, -$1.5 million in Q3 2025, and $1.7 million in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn |
| 10 | Zenas BioPharma | 1.87 Bn | 748.44 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 581,000.00 |
| Jun 30, 2026 | 581,000.00 |
| Mar 31, 2026 | 367,000.00 |
| Mar 31, 2026 | 367,000.00 |
| Sep 30, 2025 | -1.55 Mn |
| Sep 30, 2025 | -1.55 Mn |
| Jun 30, 2025 | 1.72 Mn |
| Jun 30, 2025 | 1.72 Mn |
| Mar 31, 2025 | 99,000.00 |
| Mar 31, 2025 | 99,000.00 |
| Dec 31, 2024 | 77,000.00 |
| Dec 31, 2024 | 77,000.00 |
| Sep 30, 2024 | 258.70 Mn |
| Sep 30, 2024 | 258.70 Mn |
| Jun 30, 2024 | 124,000.00 |
| Jun 30, 2024 | 124,000.00 |
| Mar 31, 2024 | 42,000.00 |
| Mar 31, 2024 | 42,000.00 |
| Dec 31, 2023 | 50,000.00 |
| Dec 31, 2023 | 50,000.00 |